Just In
- 15 hrs ago Heeramandi Screening: Alia Bhatt, Ananya Panday, Rashmika Mandanna And Others Serve Finest Ethnic Style!
- 16 hrs ago From Alia Bhatt To Kriti Sanon, Korean Beauty Products That Bollywood Divas Swear By
- 19 hrs ago Exclusive: On World Malaria Day 2024, Dr Shares Danger Signs Parents Must Watch Out For In Child With Malaria
- 19 hrs ago Exclusive: Expert Debunks 5 Common Misconceptions About Expectant Mothers That You Need To Steer Clear From
Don't Miss
- Movies Pavi Caretaker Box Office Collection Day 1 Prediction: Dileep's Movie Expected To Open Strongly
- Sports Who Won Yesterday's IPL Match 41? SRH vs RCB, IPL 2024 on April 25: Royal Challengers Bangalore End Losing Streak
- Finance Bajaj Group Stock Declares Rs. 60/Share Dividend: Buy Ahead of Record Date On 28 June?
- News MEA Dismisses US Human Rights Report On Manipur As 'Biased And Misinformed'
- Automobiles Royal Enfield Unveils Revolutionary Rentals & Tours Service: Check Out All Details Here
- Technology Elon Musk’s X Is Launching a TV App Similar to YouTube for Watching Videos
- Education AICTE introduces career portal for 3 million students, offering fully-sponsored trip to Silicon Valley
- Travel Escape to Kalimpong, Gangtok, and Darjeeling with IRCTC's Tour Package; Check Itinerary
COVID-19: Pfizer Vaccine's Booster Shot Can Cut Mortality From Delta Variant By 90 Per Cent: Study
The third dose of the Pfizer COVID-19 vaccine can reduce mortality due to the Delta variant of the SARS-CoV-2 virus by 90 per cent, according to a study conducted in Israel.
The research, published in The New England Journal of Medicine on Thursday, included data from participants 50 years of age or older who had received two doses of Pfizer vaccine at least five months earlier.
Jerusalem: The third dose of the Pfizer COVID-19 vaccine can reduce mortality due to the Delta variant of the SARS-CoV-2 virus by 90 per cent, according to a study conducted in Israel.
The research, published in The New England Journal of Medicine on Thursday, included data from participants 50 years of age or older who had received two doses of Pfizer vaccine at least five months earlier.
The mortality due to COVID-19 among participants who received the booster during the study period (booster group) was compared with that among participants who did not receive the booster (non-booster group).
A total of 843,208 participants met the eligibility criteria, of whom 758,118 (90 per cent) received the booster during the 54-day study period, according to the researchers, including those from Clalit Health Services and Ben-Gurion University of the Negev, Israel.
Death due to COVID-19 occurred in 65 participants in the booster group (0.16 per 100,000 persons per day) and in 137 participants in the non-booster group (2.98 per 100,000 persons per day).
"Participants who received a booster at least five months after the second dose of Pfizer had 90 per cent lower mortality due to COVID-19 than participants who did not receive a booster," the authors of the study noted.
Among participants 65 years of age or older, death from COVID-19 occurred in 60 of 470,808 participants in the booster group and in 123 of 35,208 participants in the non-booster group, the researchers said.
In those younger than 65 years of age, death from COVID-19 occurred in 5 of 287,310 participants in the booster group and in 14 of 49,882 participants in the non-booster group, they said.
Among female participants, death from COVID-19 occurred in 54 of 400,300 participants in the booster group and in 13 of 47,972 participants in the non-booster group, according to the researchers.
The emergence of the Delta variant of SARS-CoV-2 and the reduced effectiveness overtime of the Pfizer vaccine led to a resurgence of COVID-19 cases in populations that had been vaccinated early.
On July 30, 2021, the Israeli Ministry of Health approved the use of a third dose of Pfizer vaccine to cope with this resurgence.
- wellnessPaxlovid: South Korea Gets First Supply Of Pfizer's COVID-19 Pills; Read Details
- healthPfizer Vaccine Provides Partial Protection Against Omicron: Study
- healthPfizer’s Pill Is The Latest COVID Treatment To Show Promise. Here Are Some More
- healthPfizer, Astrazeneca COVID Vaccines Generate More Antibodies Than Natural Infection: Study
- disorders cureMixing And Matching Of COVID-19 Vaccine Doses? Is It Safe?
- wellnessGap Between Second And Precaution Dose Of Covid-19 Vaccine Reduced To 6 Months
- wellnessNovel Inhalable Covid-19 Vaccine Is Stable At Room Temperature: Study
- wellnessNTAGI To Review Covaxin Corbevax Data For 6-12 Years Thursday, Discuss Reducing Booster Dose Gap
- wellnessEven Vaccinated People Can Develop Long Covid, Study Finds
- wellnessBooster Dose Of COVID Vaccine Needed To Fight Against Omicron: Study
- basicsNovavax's Covid-19 Vaccine Covovax Gets Emergency Use Authorisation For 12-17 Age Group In India
- wellnessAIIMS Delhi To Start Booster Dose Trial Of Intranasal Covid Vaccine From March 11